Breaking Labaran Turai Breaking Labaran Duniya Yanke Labaran Balaguro Labaran Gwamnati Rahoton Lafiya Labarai Hakkin Tourism Sirrin Tafiya Labaran Wayar Balaguro Labaran Amurka Labarai daban -daban

WHO: Babu mace-mace daga allurar rigakafin COVID-19 da aka ruwaito

WHO: Babu mace-mace daga allurar rigakafin COVID-19 da aka ruwaito
Kakakin WHO Tarik Jasarevic
Written by Harry Johnson

Kwamitin Shawarwari na Duniya na WHO kan Tsaron Rigakafin ya sake nazarin kowane siginar lafiyar allurar rigakafin da damuwa da ke tattare da lafiyar allurar rigakafin COVID-19

Print Friendly, PDF & Email
  • Ya zuwa 9 ga Maris, sama da allurai miliyan 268 na rigakafin COVID-19 an gudanar da su a duk duniya tun farkon annobar cutar
  • Babu wani shari'ar mutuwa da aka gano wanda ya haifar da rigakafin COVID-19 har zuwa yau
  • Alurar riga kafi kan COVID-19 ba za ta rage mace-mace daga wasu dalilai ba

The Hukumar Lafiya ta Duniya (WHO) a yau yayi sharhi akan Denmark, Iceland, Italia da Norway dakatar da amfani da AstraZeneca allurar rigakafi bayan rahotannin thrombosis tsakanin waɗanda aka yiwa rigakafin.

A cewar hukumar lafiyar ta duniya, sama da mutane miliyan 268 ne aka yiwa rigakafin COVID-19 a duniya, kuma ba a tabbatar da mutuwa daga allurar ba har zuwa ranar 9 ga Maris.

"WHO na sane da cewa a matsayin matakin kariya, wasu kasashe a Tarayyar Turai sun dakatar da amfani da wani takamaiman rukuni na maganin AstraZeneca da aka rarraba a cikin EU, dangane da rahotannin cututtukan da ke tattare da jini a cikin mutanen da suka karɓi rigakafin daga wannan rukunin. . An yanke wannan shawarar a matsayin kariya yayin da aka kammala cikakken bincike, "in ji kakakin WHO Tarik Jasarevic.

"Yana da mahimmanci a lura cewa matsayin Kwamitin Tantance Riskment Riskment na Hukumar Kula da Magunguna ta Turai shi ne, fa'idodin allurar na ci gaba da fin karfin kasadarsa, kuma ana iya ci gaba da gudanar da rigakafin yayin da ake gudanar da bincike kan al'amuran da suka shafi thromboembolic events," in ji kakakin.

"Kwamitin Shawara na Duniya na WHO kan Tsaron Rigakafin (GACVS) ya sake nazarin kowane siginar lafiyar allurar rigakafi da damuwa da ke da alaƙa da rigakafin rigakafin COVID-19, kuma yana saduwa kowane mako biyu don ba wa WHO shawara game da duk wani sabon sigina na tsaro ko damuwa da ke da alaƙa da rigakafin COVID-19, ya kara da cewa.

“GACVS tana nazarin rahotannin yanzu game da maganin Astra Zeneca. Da zaran WHO ta sami cikakkiyar fahimtar waɗannan abubuwan, abubuwan da aka gano da duk wani canje-canje ga shawarwarin yanzu za a sanar da su kai tsaye ga jama'a. Alurar riga kafi kan COVID-19 ba za ta rage mace-mace daga wasu dalilai ba. Mutuwa daga wasu dalilan za su ci gaba da faruwa, gami da bayan allurar rigakafin, amma sanadiyyar hakan ba shi da nasaba, ”in ji Jasarevic.

An bayar da rahoto a ranar Alhamis cewa Denmark da wasu jihohi sun dakatar da amfani da allurar ta AstraZeneca bayan rahotannin thrombosis a tsakanin wadanda aka yiwa rigakafin. Tun da farko, Hukumar Kula da Magunguna ta Turai (EMA) ta ba da shawarar ci gaba da amfani da allurar, lura da cewa ba a tabbatar da cewa wadannan alamun sun samo asali ne daga rigakafin ba. Dangane da EMA, ya zuwa 10 ga Maris, akwai shari'o'in 30 na rikice-rikice na thromboembolic tsakanin kimanin mutane miliyan 5 da aka ba da allurar AstraZeneca. Hukumar ta jaddada cewa wannan na nufin cewa yawan adadin illar da aka samu tsakanin wadanda aka yiwa rigakafin bai wuce yawan masu kamuwa da cutar ba a cikin jama'a gaba daya.

Print Friendly, PDF & Email

Game da marubucin

Harry Johnson

Harry Johnson ya kasance editan aikin eTurboNews na kusan shekaru 20. Yana zaune a Honolulu, Hawaii, kuma asalinsa daga Turai ne. Yana jin daɗin rubutu da ɗaukar labarai.